(ICAD) icad - Ratings and Ratios

iCAD, Inc. (NASDAQ:ICAD) is a leading provider of innovative cancer detection and therapy solutions, operating through two core segments: Detection and Therapy. The company specializes in advanced imaging and radiation therapy solutions, focusing on improving patient outcomes in oncology. Its product portfolio includes ProFound AI, a cutting-edge solution for digital breast tomosynthesis and 2D mammography; PowerLook, a tool for breast density assessment; and ProFound Risk, which offers personalized breast cancer risk analysis. These solutions leverage AI and machine learning to enhance diagnostic accuracy and patient care.

Founded in 1984 under the name Howtek, Inc., the company rebranded as iCAD, Inc. in 2002 to reflect its expanded focus on medical imaging and cancer detection. Headquartered in Nashua, New Hampshire, iCAD has established itself as a key player in the medical technology sector, particularly in the areas of breast health and radiation oncology. Its commitment to innovation has positioned it at the forefront of AI-driven healthcare solutions.

From a technical standpoint, ICADs stock has shown volatility, with a 20-day average volume of 447,048 shares. The stock is currently trading at $2.25, below its 20-day SMA of $2.94 and 50-day SMA of $2.54. The 200-day SMA stands at $1.81, indicating potential long-term upside. The ATR of $0.30 reflects moderate price fluctuations. On the fundamental side, the company has a market cap of $66.94 million, with a price-to-book ratio of 2.28 and a price-to-sales ratio of 3.53. The negative return on equity (-11.58%) highlights ongoing profitability challenges.